|
|
||||||||||
|
J Am Coll Cardiol, 2003; 41:1933-1939, doi:10.1016/S0735-1097(03)00425-X © 2003 by the American College of Cardiology Foundation |
,*

* Veterans Affairs Puget Sound Health Care System, Seattle, Washington, USA
Division of Cardiology, University of Washington, Seattle, USA
Pfizer PGRD, New London, Connecticut, USA
Manuscript received September 23, 2002; revised manuscript received February 6, 2003, accepted February 20, 2003.
* Reprint requests and correspondence: Dr. Dariush Mozaffarian, VA Puget Sound Health Care System, 1660 South Columbian Way, MS 152, Seattle, Washington 98108, USA.
darymd{at}hotmail.com
OBJECTIVES: Our aim was to examine the relationships between serum hematocrit (Hct) and risk of all-cause mortality among patients with severe heart failure (HF).
BACKGROUND: Anemia occurs with increased frequency in severe HF. However, few studies have examined the impact of anemia on mortality in this population.
METHODS: Using a prospective cohort design, we evaluated the relationships between baseline serum Hct and mortality among 1,130 patients with left ventricular EF <30% and New York Heart Association functional class IIIB or IV HF treated with angiotensin-converting enzyme inhibitors, diuretics, and digitalis. Mortality was ascertained by centralized adjudication.
RESULTS: The mean Hct was 41.8% (range 25.4% to 58.8%). Over 15 months of mean follow-up, there were 407 deaths (29 per 100 person-years). After adjustment for potential confounders, those in the lowest quintile of Hct (range 25.4% to 37.5%) had a 52% higher risk of death (hazard ratio 1.52, 95% confidence interval 1.11 to 2.10), compared with the highest quintile (range 46.1% to 58.8%). Within the lowest quintile of Hct, each 1% decrease in Hct was associated with an 11% higher risk of death (p < 0.01), whereas within the four higher quintiles of Hct, Hct was not associated with total mortality. Evaluation of different causes of death indicated that a lower Hct was strongly associated with death from progressive HF, rather than sudden death or other deaths.
CONCLUSIONS: Among patients with severe HF, anemia is a significant independent risk factor for death, with a progressively higher risk with increasing severity of anemia. Further investigation of the etiologies, prevention, and treatment of anemia in severe HF is warranted.
| ||||||||||||||||||
This article has been cited by other articles:
![]() |
H. F. Groenveld, J. L. Januzzi, K. Damman, J. van Wijngaarden, H. L. Hillege, D. J. van Veldhuisen, and P. van der Meer Anemia and Mortality in Heart Failure Patients: A Systematic Review and Meta-Analysis J. Am. Coll. Cardiol., September 2, 2008; 52(10): 818 - 827. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.H. W. Tang, W. Tong, A. Jain, G. S. Francis, C. M. Harris, and J. B. Young Evaluation and long-term prognosis of new-onset, transient, and persistent anemia in ambulatory patients with chronic heart failure. J. Am. Coll. Cardiol., February 5, 2008; 51(5): 569 - 576. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Ghali, I. S. Anand, W. T. Abraham, G. C. Fonarow, B. Greenberg, H. Krum, B. M. Massie, S. M. Wasserman, M.-L. Trotman, Y. Sun, et al. Randomized Double-Blind Trial of Darbepoetin Alfa in Patients With Symptomatic Heart Failure and Anemia Circulation, January 29, 2008; 117(4): 526 - 535. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Spence Medical and economic impact of anemia in hospitalized patients Am. J. Health Syst. Pharm., August 15, 2007; 64(16_Supplement_11): S3 - S10. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Ponikowski, S. D. Anker, J. Szachniewicz, D. Okonko, M. Ledwidge, R. Zymlinski, E. Ryan, S. M. Wasserman, N. Baker, D. Rosser, et al. Effect of Darbepoetin Alfa on Exercise Tolerance in Anemic Patients With Symptomatic Chronic Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial J. Am. Coll. Cardiol., February 20, 2007; 49(7): 753 - 762. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Dec Anemia in Heart Failure: Time to Rethink Its Etiology and Treatment? J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2490 - 2492. [Full Text] [PDF] |
||||
![]() |
J D Newton and I B Squire Glucose and haemoglobin in the assessment of prognosis after first hospitalisation for heart failure Heart, October 1, 2006; 92(10): 1441 - 1446. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. P. Bolger, F. R. Bartlett, H. S. Penston, J. O'Leary, N. Pollock, R. Kaprielian, and C. M. Chapman Intravenous Iron Alone for the Treatment of Anemia in Patients With Chronic Heart Failure J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1225 - 1227. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Go, J. Yang, L. M. Ackerson, K. Lepper, S. Robbins, B. M. Massie, and M. G. Shlipak Hemoglobin Level, Chronic Kidney Disease, and the Risks of Death and Hospitalization in Adults With Chronic Heart Failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) Study Circulation, June 13, 2006; 113(23): 2713 - 2723. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Komajda, S. D. Anker, A. Charlesworth, D. Okonko, M. Metra, A. Di Lenarda, W. Remme, C. Moullet, K. Swedberg, J. G.F. Cleland, et al. The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET Eur. Heart J., June 2, 2006; 27(12): 1440 - 1446. [Abstract] [Full Text] [PDF] |
||||
![]() |
L Grigorian Shamagian, A Varela Roman, J M Garcia-Acuna, P Mazon Ramos, A Virgos Lamela, and J R Gonzalez-Juanatey Anaemia is associated with higher mortality among patients with heart failure with preserved systolic function Heart, June 1, 2006; 92(6): 780 - 784. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-D. Tang and S. D. Katz Anemia in Chronic Heart Failure: Prevalence, Etiology, Clinical Correlates, and Treatment Options Circulation, May 23, 2006; 113(20): 2454 - 2461. [Full Text] [PDF] |
||||
![]() |
B. F. Culleton, B. J. Manns, J. Zhang, M. Tonelli, S. Klarenbach, and B. R. Hemmelgarn Impact of anemia on hospitalization and mortality in older adults Blood, May 15, 2006; 107(10): 3841 - 3846. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. C. Levy, D. Mozaffarian, D. T. Linker, S. C. Sutradhar, S. D. Anker, A. B. Cropp, I. Anand, A. Maggioni, P. Burton, M. D. Sullivan, et al. The Seattle Heart Failure Model: Prediction of Survival in Heart Failure Circulation, March 21, 2006; 113(11): 1424 - 1433. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. O'Meara, T. Clayton, M. B. McEntegart, J. J.V. McMurray, C. C. Lang, S. D. Roger, J. B. Young, S. D. Solomon, C. B. Granger, J. Ostergren, et al. Clinical Correlates and Consequences of Anemia in a Broad Spectrum of Patients With Heart Failure: Results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program Circulation, February 21, 2006; 113(7): 986 - 994. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Opasich, M. Cazzola, L. Scelsi, S. De Feo, E. Bosimini, R. Lagioia, O. Febo, R. Ferrari, A. Fucili, R. Moratti, et al. Blunted erythropoietin production and defective iron supply for erythropoiesis as major causes of anaemia in patients with chronic heart failure Eur. Heart J., November 1, 2005; 26(21): 2232 - 2237. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. T. Vlagopoulos, H. Tighiouart, D. E. Weiner, J. Griffith, D. Pettitt, D. N. Salem, A. S. Levey, and M. J. Sarnak Anemia as a Risk Factor for Cardiovascular Disease and All-Cause Mortality in Diabetes: The Impact of Chronic Kidney Disease J. Am. Soc. Nephrol., November 1, 2005; 16(11): 3403 - 3410. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Spivak Anemia in the Elderly: Time for New Blood in Old Vessels? Arch Intern Med, October 24, 2005; 165(19): 2187 - 2189. [Full Text] [PDF] |
||||
![]() |
M. Kosiborod, J. P. Curtis, Y. Wang, G. L. Smith, F. A. Masoudi, J. M. Foody, E. P. Havranek, and H. M. Krumholz Anemia and Outcomes in Patients With Heart Failure: A Study From the National Heart Care Project Arch Intern Med, October 24, 2005; 165(19): 2237 - 2244. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. van der Meer, E. Lipsic, B. D. Westenbrink, R. M.A. van de Wal, R. G. Schoemaker, E. Vellenga, D. J. van Veldhuisen, A. A. Voors, and W. H. van Gilst Levels of Hematopoiesis Inhibitor N-Acetyl-Seryl-Aspartyl-Lysyl-Proline Partially Explain the Occurrence of Anemia in Heart Failure Circulation, September 20, 2005; 112(12): 1743 - 1747. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Philipp, H. Ollmann, T. Schink, R. Dietz, F. C. Luft, and R. Willenbrock The impact of anaemia and kidney function in congestive heart failure and preserved systolic function Nephrol. Dial. Transplant., May 1, 2005; 20(5): 915 - 919. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ishani, E. Weinhandl, Z. Zhao, D. T. Gilbertson, A. J. Collins, S. Yusuf, and C. A. Herzog Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction J. Am. Coll. Cardiol., February 1, 2005; 45(3): 391 - 399. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J.V. McMurray and M. A. Pfeffer The year in heart failure J. Am. Coll. Cardiol., December 21, 2004; 44(12): 2398 - 2405. [Full Text] [PDF] |
||||
![]() |
K. Caiola and J. W. Cheng Use of Erythropoietin in Heart Failure Management Ann. Pharmacother., December 1, 2004; 38(12): 2145 - 2149. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.M. Felker, K. F. Adams Jr, W. A. Gattis, and C. M. O'Connor Anemia as a risk factor and therapeutic target in heart failure J. Am. Coll. Cardiol., September 1, 2004; 44(5): 959 - 966. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. G. Shlipak, G. L. Smith, S. S. Rathore, B. M. Massie, and H. M. Krumholz Renal Function, Digoxin Therapy, and Heart Failure Outcomes: Evidence from the Digoxin Intervention Group Trial J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2195 - 2203. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Anand, J. J.V. McMurray, J. Whitmore, M. Warren, A. Pham, M. A. McCamish, and P. B.J. Burton Anemia and Its Relationship to Clinical Outcome in Heart Failure Circulation, July 13, 2004; 110(2): 149 - 154. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. van der Meer, A. A. Voors, E. Lipsic, T. D. J. Smilde, W. H. van Gilst, and D. J. van Veldhuisen Prognostic value of plasma erythropoietin on mortality in patients with chronic heart failure J. Am. Coll. Cardiol., July 7, 2004; 44(1): 63 - 67. [Abstract] [Full Text] [PDF] |
||||
![]() |
C Nielson and D Wingete Intensive care and invasive ventilation in the elderly patient, implications of chronic lung disease and comorbidities Chronic Respiratory Disease, January 1, 2004; 1(1): 43 - 54. [Abstract] [PDF] |
||||
![]() |
H. Taegtmeyer and S. Sharma Anemia and energy depletion J. Am. Coll. Cardiol., December 3, 2003; 42(11): 2030 - 2030. [Full Text] [PDF] |
||||
![]() |
D. Mozaffarian and W. Levy Anemia and energy depletion: reply J. Am. Coll. Cardiol., December 3, 2003; 42(11): 2030 - 2030. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |